Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib with Cisplatin/5-FU or Cisplatin/Capecitabine in Solid Tumors
NCT02648425Phase 1Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of varlitinib in solid tumor (2 arms), sponsored by ASLAN Pharmaceuticals. Primary endpoint: Safety and Tolerability of ASLAN001. Started Aug 2014; status: completed.
02
Drugs
varlitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02648425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648425.